Centre for Drug Candidate Optimisation

Established in 2003, the Centre for Drug Candidate Optimisation (CDCO) was established in 2003 to fill a critical gap in drug discovery by providing translational expertise on absorption, distribution, metabolism and excretion (ADME) and pharmacokinetic (PK) properties of investigational drug candidates. Identifying PK liabilities during drug discovery is essential to guide appropriate structural modifications and identify strategies to mitigate risks during development.

The CDCO provides expertise and infrastructure to non-commercial and commercial users, with costs dependent on the specific arrangement (fee for service, collaboration, or another model). Reduced rates are available for longer-term projects. 

The identity of many of CDCO’s industry collaborators and their specific programs is protected by commercial-in-confidence agreements; however some companies have agreed to be publically named as collaborators including Biota, Bionomics, Prana Biotechnology, the CRC for Cancer Therapeutics, the Medicines for Malaria Venture (Geneva) and the Drugs for Neglected Diseases initiative (Geneva). Over the past 10 years, the CDCO has collaborated with many Australian biotech start-up companies, and maintains close links with companies with the biotech community. The CDCO has contributed to Australian and international drug discovery programs that have progressed more than 20 drug candidates into clinical trials. 

Contact:  Prof Susan Charman/Dr Andrew Powell

Email:  susan.charman@monash.edu/andrew.powell@monash.edu

Phone:  +61 (0)3 9903 9626/+61 (0)3 9903 9149